RAPT Therapeutics Stock Soars 63% in Pre-Market on Nasdaq After GSK’s $2.2 Billion Acquisition Deal

On January 20, 2026, RAPT Therapeutics stock made a sharp move, surging over 63% in pre-market trading on the Nasdaq. This surge followed news that GSK plc agreed to buy the biotech company in an all-cash deal worth about $2.2 billion. This rally grabbed the attention of investors and traders worldwide. The deal represents a significant milestone for RAPT’s clinical program and signals growing confidence in its pipeline.